Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ERock Inc (EROC)
NYSEIndustrialsElectrical Equipment & PartsSnapshot 2026-11-04
$7.94-11.38%
Close 2026-11-04 · 1-day change
NYSEIndustrialsElectrical Equipment & PartsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
0.49 → 0.49 EPS · FY ending Dec 31, 2027 · 3 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 3; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for EROC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Effectively utilize IPO proceeds for growth | A supporting condition in ERock Inc's published investment case. The stated target is Utilize IPO proceeds effectively to support growth. | Intact | Failure to effectively allocate IPO proceeds | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextNewly stated in 2026-Q2. The company completed an IPO issuing 27.9 million shares at $21.50 each and issued shares to pre-IPO holders. This capital allocation event is a one-time milestone supporting funding needs, with no prior quarters stating this priority. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
EROC is a high-risk, cyclical industrial business with a limited operating record in the evidence provided. Management is stable, but the thesis is insufficiently established because recent financial history is too limited to assess the broader trend.
The snapshot gives no valuation multiples or peer comparison, so whether EROC is cheap or expensive and what expectations are reflected cannot be assessed. It reports low valuation fragility, meaning no identified signal that expectations are unusually concentrated, but that does not establish an expectations gap.
Near term, the recent earnings beat is a positive data point, but revenue fell from $68.5 million in 2025-Q2 to $39.9 million in 2026-Q2, and operating losses widened over that period. Net income improved in 2026-Q2 versus the prior quarter, while management’s efforts to improve profitability and scale operations show mixed progress.
Over the next one to three years, the thesis hinges on revenue recovery and sustained improvement in operating losses. Strong results and guidance from industrial bellwethers could support the sector backdrop, while weaker reports or continued softening in jobs data could add pressure to cyclical businesses like EROC.
The multi-year view is unresolved: management is stable, but high risk, declining revenue, and limited progress on operating losses weigh on the business case. The evidence is low confidence and does not yet show whether recent positive signals can persist. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Reduce operating losses and improve profitability | A supporting condition in ERock Inc's published investment case. The stated target is Operating income improves from -$19.8M in Q2 2026. | Under Pressure | Operating income remains below -$19.8M | Operating income: $-19.848M FY2026-Q2; GAAP. Published target: Operating income improves from -$19.8M in Q2 2026. Target period is not explicitly aligned with this observation. Aug 12, 2026-19,848,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 3 of last 3 quarters. Operating income was negative $0.5M in 2025-Q2 and worsened to negative $19.8M in 2026-Q2, while net income improved from negative $17.2M in 2026-Q1 to negative $3.0M in 2026-Q2. The trajectory shows limited progress on operating losses but some improvement in net income, indicating partial delivery on loss reduction. Delivery assessment Oct 31, 2026 |
Achieve FY2026 revenue between $435M and $465M | A primary condition in ERock Inc's published investment case. The stated target is >=435M. | Intact | FY2026 revenue falls below $435M | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of last 5 quarters. Revenue declined from $68.5M in 2025-Q2 to $39.9M in 2026-Q2, indicating challenges in scaling operations. Management continues to emphasize revenue growth, but the financials show a declining trajectory, reflecting limited progress. Delivery assessment Oct 31, 2026 |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.50 → $0.49 · observed estimates
$1.44B → $1.44B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-07 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-08 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-09 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-10 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-11 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-12 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-13 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-14 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-15 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-16 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-17 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-18 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-19 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-20 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-21 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-22 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-23 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-24 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-25 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-26 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-27 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-28 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-29 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-09-30 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-10-01 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-10-02 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-10-03 | $0.50 | $1,440,000,000 | 3 / 5 |
| 2026-10-04 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-05 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-06 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-07 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-08 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-09 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-10 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-11 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-12 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-13 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-14 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-15 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-16 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-17 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-18 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-19 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-20 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-21 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-22 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-23 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-24 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-25 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-26 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-27 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-28 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-29 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-30 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-10-31 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-11-01 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-11-02 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-11-03 | $0.49 | $1,440,000,000 | 3 / 5 |
| 2026-11-04 | $0.49 | $1,440,000,000 | 3 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.